Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy

被引:2
作者
Cooper, Katy [1 ]
Nalbant, Gamze [1 ]
Sutton, Anthea [1 ]
Harnan, Sue [1 ]
Thokala, Praveen [1 ]
Chilcott, Jim [1 ]
McNeill, Alisdair [1 ]
Bessey, Alice [1 ]
机构
[1] Univ Sheffield, Sch Med & Populat Hlth, Sheffield S1 4DA, England
关键词
systematic review; spinal muscular atrophy; presymptomatic treatment; efficacy of treatment; ONASEMNOGENE ABEPARVOVEC; CHILDREN;
D O I
10.3390/ijns10030056
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Spinal muscular atrophy (SMA) causes the degeneration of motor neurons in the spinal cord. Treatments including nusinersen, risdiplam, and onasemnogene abeparvovec have been shown to be effective in reducing symptoms, with recent studies suggesting greater effectiveness when treatment is initiated in the presymptomatic stage. This systematic review synthesises findings from prospective studies of presymptomatic treatment for 5q SMA published up to December 2023. The review identified three single-arm interventional studies of presymptomatic treatment (NURTURE, RAINBOWFISH, and SPR1NT), six observational studies comparing presymptomatic or screened cohorts versus symptomatic cohorts, and twelve follow-up studies of screened cohorts only (i.e., babies identified via newborn screening for SMA). Babies with three SMN2 copies met most motor milestones in the NURTURE study of nusinersen and in the SPR1NT study of onasemnogene abeparvovec. Babies with two SMN2 copies in these two studies met most motor milestones but with some delays, and some required ventilatory or feeding support. The RAINBOWFISH study of risdiplam is ongoing. Na & iuml;ve comparisons of presymptomatic treatment in SPR1NT, versus untreated or symptomatic treatment cohorts, suggested improved outcomes in patients treated presymptomatically. Comparative observational studies supported the finding that presymptomatic treatment, and early treatment following screening, may improve outcomes compared with treatment at the symptomatic stage. Further research should assess the long-term clinical outcomes and cost-effectiveness of presymptomatic treatment for SMA.
引用
收藏
页数:31
相关论文
共 57 条
  • [1] Albrechtsen SS, 2020, DAN MED J, V67
  • [2] Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review
    Aragon-Gawinska, Karolina
    Mouraux, Charlotte
    Dangouloff, Tamara
    Servais, Laurent
    [J]. GENES, 2023, 14 (07)
  • [3] Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
    Blair, Hannah A.
    [J]. CNS DRUGS, 2022, 36 (09) : 995 - 1005
  • [4] Newborn Screening for SMA - Can a Wait-and-See Strategy be Responsibly Justified in Patients With Four SMN2 Copies?
    Blaschek, Astrid
    Koelbel, Heike
    Schwartz, Oliver
    Koehler, Cornelia
    Glaeser, Dieter
    Eggermann, Katja
    Hannibal, Iris
    Schara-Schmidt, Ulrike
    Mueller-Felber, Wolfgang
    Vill, Katharina
    [J]. JOURNAL OF NEUROMUSCULAR DISEASES, 2022, 9 (05) : 597 - 605
  • [5] Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
    Boemer, Francois
    Caberg, Jean-Hubert
    Beckers, Pablo
    Dideberg, Vinciane
    di Fiore, Samantha
    Bours, Vincent
    Marie, Sandrine
    Dewulf, Joseph
    Marcelis, Lionel
    Deconinck, Nicolas
    Daron, Aurore
    Blasco-Perez, Laura
    Tizzano, Eduardo
    Hiligsmann, Mickael
    Lombet, Jacques
    Pereira, Tatiana
    Lopez-Granados, Lucia
    Shalchian-Tehran, Sarvnaz
    van Assche, Veronique
    Willems, Arabelle
    Huybrechts, Sofie
    Mast, Benedicte
    van Olden, Rudolf
    Dangouloff, Tamara
    Servais, Laurent
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [6] Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
    Chaplin, Marty
    Bresnahan, Rebecca
    Fleeman, Nigel
    Mahon, James
    Houten, Rachel
    Beale, Sophie
    Boland, Angela
    Dundar, Yenal
    Marsden, Ashley
    Munot, Pinki
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (06) : 863 - 875
  • [7] Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies
    Chiriboga, Claudia A.
    [J]. PEDIATRIC DRUGS, 2022, 24 (06) : 585 - 602
  • [8] ClinicalTrials.gov, A Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (RAINBOWFISH)
  • [9] Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study
    Crawford, Thomas J.
    Swoboda, Kathryn C.
    De Vivo, Darryl
    Bertini, Enrico
    Hwu, Wuh-Liang S.
    Finkel, Richard
    Kirschner, Janbernd L.
    Kuntz, Nancy
    Nazario, Aledie Navas A.
    Parsons, Julie
    Pechmann, Astrid M.
    Ryan, M. Monique M. J.
    Butterfield, Russell
    Topaloglu, Haluk
    Ben-Omran, Tawfeg A.
    Sansone, Valeria
    Jong, Yuh-Jyh
    Shu, Francy
    Zhu, Cong
    Raynaud, Stephanie R.
    Lago, Tiffany D.
    Paradis, Angela
    Foster, Richard
    Chin, Russell
    Berger, Zdenek
    NURTURE Study Grp
    [J]. MUSCLE & NERVE, 2023, 68 (02) : 157 - 170
  • [10] Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening
    Dangouloff, Tamara
    Hiligsmann, Mickael
    Deconinck, Nicolas
    D'Amico, Adele
    Seferian, Andreea M.
    Boemer, Francois
    Servais, Laurent
    [J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2023, 65 (01) : 67 - 77